WO1992000085A1 - Freeze-dried hybrid mild pumpkin and drugs containing same - Google Patents

Freeze-dried hybrid mild pumpkin and drugs containing same Download PDF

Info

Publication number
WO1992000085A1
WO1992000085A1 PCT/FR1991/000486 FR9100486W WO9200085A1 WO 1992000085 A1 WO1992000085 A1 WO 1992000085A1 FR 9100486 W FR9100486 W FR 9100486W WO 9200085 A1 WO9200085 A1 WO 9200085A1
Authority
WO
WIPO (PCT)
Prior art keywords
content
freeze
pumpkin
lyophilisate
mild
Prior art date
Application number
PCT/FR1991/000486
Other languages
French (fr)
Inventor
André Rougereau
Original Assignee
Rougereau Andre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rougereau Andre filed Critical Rougereau Andre
Priority to KR1019920700366A priority Critical patent/KR920702227A/en
Publication of WO1992000085A1 publication Critical patent/WO1992000085A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Definitions

  • Cucurbits are a family of annual broadleaf plants widespread in all countries of the world whose edible fruits such as squash, pumpkins, pumpkins (cucurbita), melons, cucumbers (cucumis), watermelons (citrullus), casays (Lagenaria) are widely consumed .
  • Bryone Bryonia
  • Echallium donkey cucumber
  • the present invention relates to a new lyophilisate of total extract of hybrid sweet pumpkin.
  • This lyophilisate is obtained from a variety selected for 12 years by successive hybridizations.
  • the plant is raised under organic cultivation contract.
  • the controls are carried out periodically at the level of the ground and the runoff during and at the end of production.
  • This pumpkin picked at maturity, washed, crushed with bark, pulp and seeds is lyophilized according to a conventional process, then made bacteriologically stable by irradiation with gamma radiation.
  • the genetic stability obtained by a tightly controlled culture over a long period facilitates the standardization of the physico-chemical constants of the lyophilisate thus obtained. It has the following characteristics:
  • Fine, homogeneous powder and indelible yellow-orange color Fine, homogeneous powder and indelible yellow-orange color.
  • Herbal odor, floury taste Herbal odor, floury taste.
  • the assay is carried out by ultraviolet spectrophotometry using a Perkin-Elmer device, by comparison with a control batch of ⁇ carotene, reference Merck 2236 according to FIGS. 2 and 3.
  • the product is insoluble in water, sparingly soluble in ethanol and methanol, sparingly soluble in ether and oils, soluble in chloroform.
  • the seed oil by incorporating more lipids and more unsaturated fatty acids, linoleic and linolenic, to it is itself an important factor of the penetrating power of topical preparations for dermatological and cosmetic use made with the compound.
  • the half-life of the lyophilisate has been determined to the extent of four to five hours for a therapeutic dose of 100 mg / kg / day.
  • mice and rats being greater than 5 g per kilo;
  • Oral preparation in the form of a microencapsulated granule allowing, thanks to a support, the release in less than an hour of a half dose of 1.5 g of active principle and five hours after a second dose of 1.5 g .
  • Topical preparation (gel, cream or ointment) allowing, thanks to an excipient, oily or not, suitably chosen an application every 2 or 3 hours on the injured parts; an active ingredient dosage of between 2 and 10% provides rapid disappearance of the inflammation and / or pain.

Abstract

The novel freeze-dried total extract of hybrid mild pumpkin has a homogeneous powdery appearance, a permanent yellow-organe colour, a pH between 6.44 and 6.47, a carbohydrate content of 63-67 %, a lipid content of 6 % ± 0.5 %, a protein content of 10 % ± 1 %, and a total carotenoid content of 25 mg ± 10 % per gramme of the freeze-dried extract. This substance has therapeutical applications, particularly as an orally or transcutaneously administered drug having an anti-inflammatory, antipyretic and pain-killing activity at least as great as that of betamethasone.

Description

L yoph i l i sat de p iti ron d oux hybride et méd icaments l e contenant.  L yoph i l i sat de p iti ron d oux hybride et medicaments l e contain.
Les Cucurbitacées constituent une famille de plantes dicotylédones annuelles répandues dans tous les pays du monde dont les fruits comestibles tels que courges, citrouilles, potirons (cucurbita), melons, concombres (cucumis), pastèques (citrullus), caiebasses (Lagenaria) sont largement consommés.  Cucurbits are a family of annual broadleaf plants widespread in all countries of the world whose edible fruits such as squash, pumpkins, pumpkins (cucurbita), melons, cucumbers (cucumis), watermelons (citrullus), casays (Lagenaria) are widely consumed .
Depuis la plus haute Antiquité, ces plantes sont connues pour leurs vertus thérapeutiques bénéfiques et certaines variétés non comestibles, la Bryone (Bryonia), le concombre d'âne (Echallium) pour leur toxicité.  Since ancient times, these plants have been known for their beneficial therapeutic properties and certain inedible varieties, Bryone (Bryonia), donkey cucumber (Echallium) for their toxicity.
Elles ont donné lieu à de multiples recherches botaniques, pharmacochimiques, pharmacodynamiques et à des applications thérapeutiques diverses ainsi qu'à de très nombreuses publications et demandes de brevets.  They have given rise to numerous botanical, pharmacochemical, pharmacodynamic research and various therapeutic applications as well as to numerous publications and patent applications.
Ces recherches se sont heurtées à la complexité chimique de ces plantes et en conséquence à l'instabilité des résultats recueillis, en raison de la variété infinie des différentes espèces étudiées, non seulement, l'une par rapport à l'autre, mais encore dans chaque espèce à la variation des sources, des saisons, des années, des terrains ensemencés, des façons culturales.  This research came up against the chemical complexity of these plants and consequently the instability of the results collected, due to the infinite variety of the different species studied, not only in relation to each other, but also in each species with the variation of the sources, the seasons, the years, the sown grounds, the cultural ways.
La présente invention est relative à un nouveau lyophilisât d'extrait total de potiron doux hybride.  The present invention relates to a new lyophilisate of total extract of hybrid sweet pumpkin.
Ce lyophilisât est obtenu à partir d'une variété sélectionnée depuis 12 ans par hybridations successives. La plante est élevée sous contrat de culture biologique. Les contrôles sont effectués périodiquement au niveau du terrain et des eaux de ruissellement au cours et en fin de production. Ce potiron cueilli à maturité, lavé, broyé avec écorce, pulpe et pépins est lyophilisé selon un procédé classique, puis rendu bactériologiquement stable par irradiation au rayonnement gamma.  This lyophilisate is obtained from a variety selected for 12 years by successive hybridizations. The plant is raised under organic cultivation contract. The controls are carried out periodically at the level of the ground and the runoff during and at the end of production. This pumpkin picked at maturity, washed, crushed with bark, pulp and seeds is lyophilized according to a conventional process, then made bacteriologically stable by irradiation with gamma radiation.
La stabilité génétique obtenue par une culture étroitement contrôlée sur une longue période, facilite la standardisation des constantes physico-chimiques du lyophilisât ainsi obtenu. Celui-ci présente les caractéristiques suivantes :The genetic stability obtained by a tightly controlled culture over a long period, facilitates the standardization of the physico-chemical constants of the lyophilisate thus obtained. It has the following characteristics:
Caractères macroscopiques et organoleptiques Macroscopic and organoleptic characters
Poudre fine, homogène et couleur jaune-orange indélébile.  Fine, homogeneous powder and indelible yellow-orange color.
Odeur herbacée, goût farineux.  Herbal odor, floury taste.
Caractères macroscopiques  Macroscopic characters
L'examen au microscope optique d'une préparation de lyophilisât dans une goutte d'eau distillée selon la Fig. 1 décèle la présence de fibres et l'absence de grains d'amidon allongés.  Examination under an optical microscope of a lyophilisate preparation in a drop of distilled water according to FIG. 1 detects the presence of fibers and the absence of elongated starch grains.
Caractères bactériologigues  Bacteriological characters
- quantité de germes aérobies mesophiles inférieure ou égale à 5,0. 102. - quantity of aerobic mesophilic germs less than or equal to 5.0. 10 2 .
- quantité de levures et moisissures inférieure ou égale à 5,0. 102. - quantity of yeast and mold less than or equal to 5.0. 10 2 .
- absence de germes pathogènes, à savoir absence : - absence of pathogenic germs, namely absence:
- d'Escherichia Coli - from Escherichia Coli
- de Staphylococcus aureus  - Staphylococcus aureus
- de Pseudomonas aeruginosa  - of Pseudomonas aeruginosa
- de Salmonella typhimurium  - of Salmonella typhimurium
Caractères physico-chimiques  Physico-chemical characters
- pH compris entre 6,44 et 6,47  - pH between 6.44 and 6.47
- métaux lourds < 2ppm  - heavy metals <2ppm
- teneur en glucides comprise entre 63 et 67 % - teneur en lipides de 6% ± 0,5  - carbohydrate content between 63 and 67% - lipid content of 6% ± 0.5
- teneur en protéines de 10% ± 1%  - protein content of 10% ± 1%
- teneur en carotenoïdes totaux de 25mg ± 10% par gramme de lyophilisât.  - total carotenoid content of 25mg ± 10% per gram of lyophilisate.
Le dosage est réalisé par spectrophotométrie en ultra-violet à l'aide d'un appareil Perkin-Elmer , par comparaison avec un lot témoin de β carotène, référence Merck 2236 selon les figures 2 et 3.  The assay is carried out by ultraviolet spectrophotometry using a Perkin-Elmer device, by comparison with a control batch of β carotene, reference Merck 2236 according to FIGS. 2 and 3.
Le produit est insoluble dans l'eau, peu soluble dans l'éthanol et le méthanol, modérément soluble dans l'éther et les huiles, soluble dans le chloroforme.  The product is insoluble in water, sparingly soluble in ethanol and methanol, sparingly soluble in ether and oils, soluble in chloroform.
La conservation de ces paramètres est liée au stockage du produit à l'abri des phénomènes de photosynthèse ou d'oxydation dus à la chaleur. L'étude pharma cocinétiqne du lyophilisât révèle que la richesse en provitamines A (β carotène) et en lipides de ce lyophilisât est trois fois plus importante que les teneurs correspondantes du potiron courant ou de la carotte; par sa forte concentration en caroténoxdes, le composé induit la bio-synthèse du Retinol et favorise une régénération cellulaire rapide accélérant le processus de cicatrisation par stimulation de la mitose cellulaire.The conservation of these parameters is linked to the storage of the product away from photosynthesis or oxidation due to heat. The cocinetic pharma study of lyophilisate reveals that the richness in provitamins A (β carotene) and in lipids of this lyophilisate is three times greater than the corresponding contents of common pumpkin or carrot; by its high concentration of carotenoxdes, the compound induces the bio-synthesis of Retinol and promotes rapid cell regeneration accelerating the healing process by stimulation of cell mitosis.
L'huile de pépins en incorporant plus de lipides et plus d'acides gras insaturés, linoléiques et linoléniques, à celui-ci est elle-même un facteur important du pouvoir de pénétration des préparations topiques à usage dermatologique et cosmétique réalisés avec le composé. La demi-vie du lyophilisât a été déterminée dans la mesure de quatre à cinq heures pour une dose thérapeutique de 100 mg/kilo/jour. The seed oil by incorporating more lipids and more unsaturated fatty acids, linoleic and linolenic, to it is itself an important factor of the penetrating power of topical preparations for dermatological and cosmetic use made with the compound. The half-life of the lyophilisate has been determined to the extent of four to five hours for a therapeutic dose of 100 mg / kg / day.
L'étude t.oxicol ngigiift de ce composé a montré :  The t.oxicol ngigiift study of this compound showed:
- une très faible toxicité aiguë, la DL 50 déterminée per os chez la souris et le rat étant supérieure à 5 g par kilo;  - very low acute toxicity, the LD 50 determined per os in mice and rats being greater than 5 g per kilo;
- une parfaite tolérance après six mois d'administration répétée chez le rat des deux sexes, objectivée par les examens pondéraux, hématologiques, biochimiques et anatomo-pathologiques  - perfect tolerance after six months of repeated administration in rats of both sexes, demonstrated by weight, hematological, biochemical and anatomo-pathological examinations
L'étude pharmaenlogique : l'activité antiinflammatoire a été mise en évidence tant per os que par voie topique selon les méthodes de :  The pharmaenlogical study: the anti-inflammatory activity was demonstrated both per os and topically according to the methods of:
- l'oedème à la carragénine  - carrageenan edema
- l'oedème au kaolin.  - edema with kaolin.
L'examen des résultats donnés figure 4 montre que le lypohilisat de potiron administré tant en poudre par la voie orale qu'en gel par la voie cutanée possède une activité anti-inflammatoire hautement significative la première heure et importante les deuxième et troisième heures après chaque prise. Dans les mêmes conditions expérimentales, l'action de la betamethasone s'est montrée significative à la première heure, non significative à la deuxième heure, nulle à la troisième. L'activité analgésique a été recherchée et objectivée chez le rat selon la technique de La Belle etThe examination of the results given in FIG. 4 shows that the pumpkin hypohilisate administered both in powder form by the oral route and in gel by the cutaneous route has a highly significant anti-inflammatory activity the first hour and significant the second and third hours after each taken. Under the same experimental conditions, the action of betamethasone was shown to be significant at the first hour, not significant at the second hour, zero at the third. The analgesic activity was sought and objectified in rats according to the La Belle technique and
Tislow. Les résultats consignés dans la figure 5 montrent que le lyophilisât testé comparativement à la betamethasone possède une activité égale, voire supérieure à celle-ci. Tislow. The results recorded in FIG. 5 show that the lyophilisate tested compared to betamethasone has an activity equal to, or even greater than, this.
Les exemples d'applications thérapeutiques indiqués ci-après illustrent plus en détail l'invention sans en limiter la portée, le produit pouvant être prescrit et utilisé seul ou en association avec d'autres principes actifs.  The examples of therapeutic applications indicated below illustrate the invention in more detail without limiting its scope, the product can be prescribed and used alone or in combination with other active ingredients.
EXEMPLE 1  EXAMPLE 1
Préparation orale sous forme de granulé microencapsulé permettant grâce à un support la libération en moins d'une heure d'une demi-dose d'1,5 g de principe actif et cinq heures après d'une deuxième dose d'1,5 g. Administrée selon une posologie de deux prises par jour, une le matin, l'autre le soir, cette forme pharmaceutique absorbée pendant une à deux semaines, réduit totalement les manifestations inflammatoires et douloureuses.  Oral preparation in the form of a microencapsulated granule allowing, thanks to a support, the release in less than an hour of a half dose of 1.5 g of active principle and five hours after a second dose of 1.5 g . Administered in a dosage of two doses a day, one in the morning, the other in the evening, this pharmaceutical form absorbed for one to two weeks, completely reduces inflammatory and painful manifestations.
EXEMPLE 2 EXAMPLE 2
Préparation topique (gel, crème ou pommade) permettant grâce à un excipient, huileux ou non, convenablement choisi une application toutes les 2 ou 3 heures sur les parties lésées ; un dosage de principe actif compris entre 2 et 10% procure une disparition rapide de l'inflammation et/ou de la douleur. EXEMPLE 3  Topical preparation (gel, cream or ointment) allowing, thanks to an excipient, oily or not, suitably chosen an application every 2 or 3 hours on the injured parts; an active ingredient dosage of between 2 and 10% provides rapid disappearance of the inflammation and / or pain. EXAMPLE 3
Préparation topique du principe actif suspendu à raison de 50 à 60 mg de lyophilisât dans 100 ml de liquide propulsé par un gaz inerte autorisé tel que l'azote, ce type de forme pharmaceutique étant particulièrement indiqué dans le traitement des brûlures et des escarres.  Topical preparation of the active ingredient suspended in an amount of 50 to 60 mg of lyophilisate in 100 ml of liquid propelled by an authorized inert gas such as nitrogen, this type of pharmaceutical form being particularly indicated in the treatment of burns and bedsores.

Claims

REVENDICATIONS
1. Lyophilisat d'extrait total de potiron doux hybride obtenu à partir d'une variété de cucurbitacée sélectionnée depuis douze ans par hybridations successives. La stabilité génétique obtenue par une culture étroitement contrôlée sur une longue période permet d'obtenir un principe actif présentant les caractéristiques physicochimiques suivantes : 1. Lyophilisate of total extract of hybrid sweet pumpkin obtained from a variety of cucurbits selected for twelve years by successive hybridizations. The genetic stability obtained by a tightly controlled culture over a long period makes it possible to obtain an active principle having the following physicochemical characteristics:
- pH compris entre 6,44 et 6,47  - pH between 6.44 and 6.47
- métaux lourds < 2ppm  - heavy metals <2ppm
- teneur en glucides comprise entre 63 et 67 % - carbohydrate content between 63 and 67%
- teneur en lipides de 6% ± 0,5 - lipid content of 6% ± 0.5
- teneur en protéines de 10% ± 1%  - protein content of 10% ± 1%
- teneur en carotenoïdes totaux de 25mg ± 10% par gramme de lyophilisât.  - total carotenoid content of 25mg ± 10% per gram of lyophilisate.
2. Médicament anti-inflammatoire antalgique et anti-pyrétique caractérisé en ce qu'il est constitué par un principe actif selon la revendication 1. 2. Antalgic and anti-pyretic anti-inflammatory drug, characterized in that it consists of an active principle according to claim 1.
3. Compositions pharmaceutiques caractérisées en ce qu'elles contiennent à titre de principe actif un médicament selon la revendication 2, associé à un ou plusieurs excipients et présentées en granulé, billes micro-encapsulées en granulé ou gélules, crème, gel, pommade, spray. 3. Pharmaceutical compositions characterized in that they contain, as active principle, a medicament according to claim 2, associated with one or more excipients and presented in granules, microencapsulated beads in granules or capsules, cream, gel, ointment, spray .
PCT/FR1991/000486 1990-06-22 1991-06-18 Freeze-dried hybrid mild pumpkin and drugs containing same WO1992000085A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019920700366A KR920702227A (en) 1990-06-22 1991-06-18 Lyophilized Samples of Hybrid Pumpkin and Drugs Containing the Same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9007837A FR2663543B1 (en) 1990-06-22 1990-06-22 HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME.
FR90.07837 1990-06-22

Publications (1)

Publication Number Publication Date
WO1992000085A1 true WO1992000085A1 (en) 1992-01-09

Family

ID=9397897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1991/000486 WO1992000085A1 (en) 1990-06-22 1991-06-18 Freeze-dried hybrid mild pumpkin and drugs containing same

Country Status (9)

Country Link
EP (1) EP0489144A1 (en)
JP (1) JPH05500823A (en)
KR (1) KR920702227A (en)
CA (1) CA2065032A1 (en)
FR (1) FR2663543B1 (en)
IE (1) IE912155A1 (en)
IL (1) IL98571A0 (en)
WO (1) WO1992000085A1 (en)
ZA (1) ZA914782B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671751A2 (en) 1994-03-11 1995-09-13 Cherry Mikroschalter GmbH Ergonomic keyboard
FR2732347A1 (en) * 1995-03-30 1996-10-04 Bio Media Plant extract used as cell growth factor medicament with antitumoural and anticancer activity
WO1998046244A1 (en) * 1997-04-16 1998-10-22 Feva N.V. Vegetable extract, method for preparation thereof and its applications in human and veterinary medicine
WO2003068200A2 (en) * 2002-02-15 2003-08-21 Touche Marie-Jose Novel therapeutic application for a composition

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2760366B1 (en) * 1997-03-04 2000-08-11 Harbex Limited PUMPKIN LYOPHILIZED EXTRACT HYDROLYSAT AND PROCESS FOR PRODUCING THE SAME
CN107456562A (en) * 2017-08-10 2017-12-12 靖西市民族医药协会 One kind is brought down a fever wine and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL63333C (en) * 1900-01-01
FR2522500A1 (en) * 1982-03-02 1983-09-09 Rougereau Andre Chinese pumpkin or okaido or analogous cucurbitaceae pulp - used as medicament and cosmetic having antiinflammatory, antipyretic, analgesic, antiallergic, keratolytic, skin penetrating etc. activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL63333C (en) * 1900-01-01
FR2522500A1 (en) * 1982-03-02 1983-09-09 Rougereau Andre Chinese pumpkin or okaido or analogous cucurbitaceae pulp - used as medicament and cosmetic having antiinflammatory, antipyretic, analgesic, antiallergic, keratolytic, skin penetrating etc. activity

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671751A2 (en) 1994-03-11 1995-09-13 Cherry Mikroschalter GmbH Ergonomic keyboard
FR2732347A1 (en) * 1995-03-30 1996-10-04 Bio Media Plant extract used as cell growth factor medicament with antitumoural and anticancer activity
WO1998046244A1 (en) * 1997-04-16 1998-10-22 Feva N.V. Vegetable extract, method for preparation thereof and its applications in human and veterinary medicine
WO2003068200A2 (en) * 2002-02-15 2003-08-21 Touche Marie-Jose Novel therapeutic application for a composition
FR2836046A1 (en) * 2002-02-15 2003-08-22 Marie Jose Touche NOVEL THERAPEUTIC APPLICATION OF COMPOUND A: BUTOFORM OR SCUROFORM ASSOCIATED WITH PRODUCT B: EUGENOL AND PRODUCT C: ZINC OXIDE, ADDED TO LYCOPENE
WO2003068200A3 (en) * 2002-02-15 2004-03-25 Marie-Jose Touche Novel therapeutic application for a composition

Also Published As

Publication number Publication date
EP0489144A1 (en) 1992-06-10
KR920702227A (en) 1992-09-03
JPH05500823A (en) 1993-02-18
FR2663543B1 (en) 1992-10-16
IE912155A1 (en) 1992-01-01
FR2663543A1 (en) 1991-12-27
ZA914782B (en) 1992-03-25
CA2065032A1 (en) 1991-12-23
IL98571A0 (en) 1992-07-15

Similar Documents

Publication Publication Date Title
Al-Sereiti et al. Pharmacology of rosemary (Rosmarinus officinalis Linn.) and its therapeutic potentials
EP0022046B1 (en) Drug composition based on plants and process for its preparation
CA2379581C (en) Echinacea supplement and method of manufacture
US8668944B2 (en) Topical oil for treating physical ailments and method for making and applying the same
EP1098657A1 (en) Composition for treating obesity and aesthetic treatment method
CH674617A5 (en)
FR2698791A1 (en) New extracts of cucurbita sp., Process for their preparation and medicines and cosmetics containing them.
WO1992000085A1 (en) Freeze-dried hybrid mild pumpkin and drugs containing same
US5665360A (en) Method of treating peripheral neuropathies of the feet and legs
CN1123340C (en) antiallergic agents
EP0075523B1 (en) Medicaments based on algae, and formulations thereof
BE1000189A3 (en) Pharmaceutical preparation for animal treatment.
CN113940926A (en) Application of citral and essential oil containing citral in preparation of medicine for treating acne
Manogaran et al. Anti–Inflammatory and antimicrobial activities of the root, bark and leaves of Azadirachta indica
US20070202207A1 (en) Use of naturally occurring epoxidised molecules from Vernonia Galamensis
US5665392A (en) Formulation for treating thalassemia and a process for preparing the same
FR2622800A1 (en) Process for preparing a product for combatting viral complaints, especially cutaneomucosal viral complaints, pharmaceutical compositions and medicaments obtained using this process
RU2203081C1 (en) Islacet preparation for preventing and treating tuberculosis and method for its embodiment
BE1027552B1 (en) COMPOSITION OF GINSENG AND ITS USE AS A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF STRESS
RU2722067C2 (en) Herbal medicinal liqueur and method for production thereof
CA2725770A1 (en) Plant-based compositions and uses
JP3557548B2 (en) Vitality promoting food and method for producing the same
FR2878163A1 (en) Compositions, useful to treat anxiety, comprise active ingredients of Eschscholtzia extract with Valerian extract, in association with a vehicle for oral administration of distinct dosages and for day or night administration
Danish et al. A Novel Approaches to Feverfew (Tanacetum Prthenium): A Review
Delbarre et al. Substances anti-inflammatoires non-stéroïdiquesI. Dérivés des acides 4-et 5-aminosalicyliques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991912699

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2065032

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991912699

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991912699

Country of ref document: EP